In a subset of patients with moderate-severe CD refractory to TNF antagonists participating in the phase 2b clinical trials of UST, Doherty et al. found that microbial signatures were associated with treatment response or remission (CDAI decrease ≥100 points or below 150 points, respectively) (79, 80). Here, TNF is linked to Cowden disease.